Fruquintinib - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for fruquintinib and what is the scope of freedom to operate?
Fruquintinib
is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Fruquintinib has sixty-eight patent family members in thirty-two countries.
One supplier is listed for this compound.
Summary for fruquintinib
| International Patents: | 68 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 84 |
| Patent Applications: | 139 |
| What excipients (inactive ingredients) are in fruquintinib? | fruquintinib excipients list |
| DailyMed Link: | fruquintinib at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for fruquintinib
Generic Entry Date for fruquintinib*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for fruquintinib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Peking University | N/A |
| Zhejiang Cancer Hospital | Phase 1/Phase 2 |
| Fudan University | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for fruquintinib
US Patents and Regulatory Information for fruquintinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-001 | Nov 8, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-002 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Takeda Pharms Usa | FRUZAQLA | fruquintinib | CAPSULE;ORAL | 217564-002 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for fruquintinib
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2297115 | DÉRIVÉS DE QUINAZOLINE COMME INHIBITEURS DE KDR (DIALKOXYQUINAZOLINE DERIVATIVES AS KDR INHIBITORS) | ⤷ Sign Up |
| Malaysia | 155566 | QUINAZOLINE DERIVATIVES | ⤷ Sign Up |
| Ukraine | 120371 | КРИСТАЛІЧНІ ФОРМИ 6-((6,7-ДИМЕТОКСИХІНАЗОЛІН-4-ІЛ)ОКСИ)-N,2-ДИМЕТИЛБЕНЗОФУРАН-3-КАРБОКСАМІДУ (CRYSTALLINE FORMS OF 6-((6,7-DIMETHOXYQUINAZOLIN-4-YL)OXY)-N,2- DIMETHYLBENZOFURAN-3-CARBOXAMIDE) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
